Travere Therapeutics, Inc. (TVTX) Q4 2025 Earnings Call February 19, 2026 4:30 PM EST
Company Participants
Nivi Nehra – Vice President of Corporate Communications & Investor Relations
Eric Dube – President, CEO & Director
Jula Inrig – Chief Medical Officer
Peter Heerma – Chief Commercial Officer
Chris Cline – Chief Financial Officer
William Rote – Chief Research Officer
Conference Call Participants
Vamil Divan – Guggenheim Securities, LLC, Research Division
Tyler Van Buren – TD Cowen, Research Division
Laura Chico – Wedbush Securities Inc., Research Division
Priyanka Grover – JPMorgan Chase & Co, Research Division
Joseph Schwartz – Leerink Partners LLC, Research Division
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Sadia Rahman – Wells Fargo Securities, LLC, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Jason Zemansky – BofA Securities, Research Division
Alexander Thompson – Stifel, Nicolaus & Company, Incorporated, Research Division
Yigal Nochomovitz – Citigroup Inc., Research Division
Presentation
Operator
Good afternoon, and welcome to the Travere Therapeutics Fourth Quarter and Full Year 2025 Financial Results Conference Call. Today’s call is being recorded.
At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.
Nivi Nehra
Vice President of Corporate Communications & Investor Relations
Thank you, operator. Good afternoon, and welcome to Travere Therapeutics Fourth Quarter and Full Year 2025 Financial Results and Corporate Update Call. Thank you all for joining. Today’s call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A.
Before we begin, I’d like to remind everyone that statements




